TD Cowen raises global GLP-1 sales forecast to $150B by 2030
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,344.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Mounjaro TRx/NRx scripts for the week ending 5/29/26 were ~756,700/353,700 (vs. ~796,800/388,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were ~610,800/328,300 (vs. ~659,000/360,200 last week). We see ~7% upside to '26 M+Z ests. We are monitoring the launches of LLY's Mounjaro (injectable GLP-GIP) for type 2 diabetes (T2D), and Zepbound (injectable GLP-GIP) for obesity, and Foundayo (oral GLP) given these are the company's key product cycles. Total GLP-1 TRx (LLY+Novo) grew ~32% yoy (see... More
